1.
We are presenting the results of MedSIR-sponsored SLLIP study at the #WCLC2018, which shows that liquid biopsy using Guardant360 is not inferior to standard biopsy analysis at detecting recommended targetable somatic genomic alterations in LUAC patients! #WCLC18 pic.twitter.com/WqxXGdxkq0
— MedSIR (@medsir2012) September 25, 2018
2.
Stay tuned for our #Periscope live stream today at 5:30pm right here on Twitter! Join @HosseinBorghaei of @FoxChaseCancer, @finn_corinne of @FBMH_UoM, and others in “Stage III NSCLC: Combining Immunotherapies With Standard Treatments...Who, When, Why?” #WCLC2018 pic.twitter.com/LSWgNlgHGd
— Medscape Education (@MedscapeCME) September 25, 2018
3.
#wclc2018 #nsclc #lungcancer Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450) https://t.co/zDJ2bWYaio
— Lung Doctor NL (@ExtraLucht) September 25, 2018
4.
#wclc2018 #mesothelioma Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma https://t.co/p9prYjpbIh
— Lung Doctor NL (@ExtraLucht) September 25, 2018
5.
Not a signle free spot for the plenary session today at #WCLC2018. Plenty of exiting results being presented today! pic.twitter.com/GVyhGBUkw7
— MedSIR (@medsir2012) September 25, 2018
6.
Great reminder about putting the right context around one's medical reporting! And thanks for highlighting a negative study -- follows right on @aaronecarroll's NYT piece this week: https://t.co/Jx20tobO0H #WCLC2018
— Kari Oakes (@KariOakes) September 25, 2018
7.
Very promising data Brigatinib presented today at the #WCLC2018. A new option to help ALK-positive NSCLC patients in the first-line setting!
— MedSIR (@medsir2012) September 25, 2018
8.
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM https://t.co/mAENfqA0Zi
— Bartomeu Massuti (@bmassutis) September 25, 2018
New player for the ALK+ disease, nowadays probably the metastatic lung cancer with better survival outcome. Presented at Plenary Sesion @IASLC #WCLC2018
9.
Exciting for times for CT-screening in Europe #WCLC2018 https://t.co/BFyZqWLY4S
— Mattias Johansson (@Mattias31) September 25, 2018
10.
Take home pts-
— Aparna Hegde, MD (@notahedge) September 25, 2018
🔹 PDL1 < 1%= CRT
🔹 PDL1 >/= 1%= CRT--> Durva
🔹 EGFR+ = NEJ009 (gefitinib/carbo/pem)? 🤷#lcsm #WCLC2018 @IASLC@n8pennell @JackWestMD @LeciaSequist thoughts?
11.
Roche announces positive Phase III results from its cancer #immunotherapy combination study for the initial treatment of small cell #lungcancer, to be presented at #WCLC2018. https://t.co/sZI2Gth03E $ROG $RHHBY pic.twitter.com/A2sUoPtzu8
— Roche (@Roche) September 25, 2018
12.
Original Article: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer (KEYNOTE-407) https://t.co/0dJuDsg4Ix #WCLC2018 pic.twitter.com/ndYaCV8DgU
— NEJM (@NEJM) September 25, 2018
13.
Dr. Natasha Leighl provides commentary on IMpower133 trial adding atelizumab immunotherapy to carbo/etoposide in extensive stage SCLC, noting that despite pos trial, much work remains, including biomarker work to help clarify which pts are benefiting. #WCLC2018 #LCSM pic.twitter.com/8O6kZhOKRh
— H. Jack West, MD (@JackWestMD) September 25, 2018
14.
Its official! Hell has frozen over! Dr. Liu presents IMpower133 trial that shows significant improvement in OS along w/PFS, relatively broad benefits (though not seen in pts w/brain mets), & no unexpected or prohibitive safety signals. Should be practice-changing. #WCLC2018 #LCSM pic.twitter.com/97MGRbOKbb
— H. Jack West, MD (@JackWestMD) September 25, 2018
15.
Dr. de Koning reviews NELSON trial of CT #screening in Netherlands & Belgium that shows major diffs in lung cancer diagnoses & survival, greater benefit in women > men. Impressive & important results. screening works & works well, hugely helpful in women. #WCLC2018 #LCSM pic.twitter.com/EF7ZMgQIyh
— H. Jack West, MD (@JackWestMD) September 25, 2018
16.
Original Article: Atezolizumab plus Chemotherapy in First-Line Extensive-Stage Small-Cell Lung Cancer (IMpower133) https://t.co/OXarZ8qdX3 #WCLC2018 pic.twitter.com/JncChvKtgJ
— NEJM (@NEJM) September 25, 2018
17.
Our Dr. John Heymach shared the latest results of a Phase II clinical trial testing poziotinib in #NSCLC patients with genetic mutations, including #HER2: https://t.co/tqK9ZT7qqV #WCLC2018 #CancerMoonshot #endcancer
— MD Anderson Cancer Center (@MDAndersonNews) September 25, 2018
18.
Original Article: Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer (ALTA-1L) https://t.co/ekESxenCLI #WCLC2018 pic.twitter.com/cJDFwMREes
— NEJM (@NEJM) September 25, 2018
19.
Dr. Antonia speaking at #WCLC2018 Presidential Session, giving OS update on PACIFIC. Statistically & clinically significant OS benefit, hint of higher tail on curve. Subset analysis shows no OS benefit in pts w/PD-L1 <1%. More benefit noted in pts who rec’d cis vs. carbo. #LCSM pic.twitter.com/H4yPiGm7an
— H. Jack West, MD (@JackWestMD) September 25, 2018
20.
Original Article: Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (PACIFIC OS) https://t.co/RRGqfYw34k #WCLC2018 pic.twitter.com/QeDQlpHFTO
— NEJM (@NEJM) September 25, 2018
No comments: